CCI
ALXN

Columbus Circle Investors’s Alexion Pharmaceuticals ALXN Stock Holding History

Columbus Circle Investors’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-13,700
Closed -$1.92M – 295
2017
Q3 		$1.92M Buy
+13,700
New +$1.86M 0.03% 227

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Columbus Circle Investors's ALXN Position: Q2 2018 in Review

Columbus Circle Investors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2018, closing a stake of 188,836 shares — an estimated $21M sold.

Columbus Circle Investors first reported a position in ALXN in Q2 2013 and held it in 19 quarters. The position peaked at $154M in Q4 2015. 601 funds tracked by Wall St. Rank hold ALXN as of Q2 2018.

  • Columbus Circle Investors reported no remaining Alexion Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Columbus Circle Investors sold 188,836 Alexion Pharmaceuticals shares in Q2 2018, an estimated $21M.
  • Columbus Circle Investors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 19 quarters.
  • Columbus Circle Investors's Alexion Pharmaceuticals position peaked at $154M in Q4 2015.
  • 601 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2018.

Based on Columbus Circle Investors's 13F filing for Q2 2018, filed 24 Jul 2018.